ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Testosterone Replacement Decreases Biomarkers of Cardiovascular Disease
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 39389" data-attributes="member: 3"><p>Abstract from AUA2016.org</p><hr /><p><strong>Low Serum Testosterone is Associated with Elevations in High-Sensitivity Cardiovascular Disease Biomarkers</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Authors:</strong> Alexander W. Pastuszak*, Mark C. Lindgren, Samuel J. Ohlander, Amin Herati, Houston, TX, Joel Estis, Alameda, CA, Larry I. Lipshultz, Houston, TX</p><p></p><p></p><p><strong>Abstract: MP47-05</strong> </p><p></p><p><strong>Introduction and Objectives</strong> </p><p></p><p>Significant controversy exists regarding the relationship between serum testosterone (T) levels and cardiovascular risk, with evidence supporting increased risk in men with both low and high T levels. However, few studies have assessed cardiovascular (CV) risk as a function of plasma testosterone (T) level using objective biomarkers. Here we examine the relationship between T levels and a panel of high sensitivity CVD markers. </p><p></p><p><strong>Methods</strong> </p><p></p><p>10,041 unique male patients were identified in the database of the Singulex® Clinical Laboratory (SCL), which specializes in high sensitivity (hs) CVD biomarker testing using single molecule counting (SMC) technology. Results were evaluated for total T, hs-cardiac troponin I (cTnI), endothelin-1 (ET), N-terminal pro-B-type natriuretic peptide (NTproBNP), interleukin-6, (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-17A (IL-17A). Patients were grouped by total T concentration and associations with the above biomarkers were determined. </p><p></p><p><strong>Results</strong> </p><p></p><p>Median (interquartile range) age within the cohort was 58 (48-68) years, and serum T level was 421 (305-565) ng/dL; T levels did not change with patient age (p=0.78), but were inversely related with body mass index (BMI) (P<0.0001). An inverse relationship between plasma T level and the number of men with increased CV risk was observed for 6 of 7 cardiovascular markers, including IL-6, cTnI, TNF-α, ET, NTproBNP and leptin (Table 1). In men with T <250 ng/dL, after adjusting for age, BMI, hemoglobin A1c (HbA1c) levels, hsCRP and HDL cholesterol levels, IL-6, ET, NTproBNP, and leptin remained significantly associated with increased CV risk. As plama T levels increased, however, the fraction of men with marker values above the reference range, and therefore considered at increased risk, decreased (Figure 1). </p><p></p><p><strong>Conclusions</strong> </p><p></p><p>Our findings support prior reports demonstrating increased CV risk in hypogonadal men and argue against the controversial current clinical conclusion that men on testosterone therapy may have an increased incidence of CVD. </p><p></p><p></p><p>[ATTACH]2073[/ATTACH]</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 39389, member: 3"] Abstract from AUA2016.org [HR][/HR][B]Low Serum Testosterone is Associated with Elevations in High-Sensitivity Cardiovascular Disease Biomarkers [/B] [B]Authors:[/B] Alexander W. Pastuszak*, Mark C. Lindgren, Samuel J. Ohlander, Amin Herati, Houston, TX, Joel Estis, Alameda, CA, Larry I. Lipshultz, Houston, TX [B]Abstract: MP47-05[/B] [B]Introduction and Objectives[/B] Significant controversy exists regarding the relationship between serum testosterone (T) levels and cardiovascular risk, with evidence supporting increased risk in men with both low and high T levels. However, few studies have assessed cardiovascular (CV) risk as a function of plasma testosterone (T) level using objective biomarkers. Here we examine the relationship between T levels and a panel of high sensitivity CVD markers. [B]Methods[/B] 10,041 unique male patients were identified in the database of the Singulex® Clinical Laboratory (SCL), which specializes in high sensitivity (hs) CVD biomarker testing using single molecule counting (SMC) technology. Results were evaluated for total T, hs-cardiac troponin I (cTnI), endothelin-1 (ET), N-terminal pro-B-type natriuretic peptide (NTproBNP), interleukin-6, (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-17A (IL-17A). Patients were grouped by total T concentration and associations with the above biomarkers were determined. [B]Results[/B] Median (interquartile range) age within the cohort was 58 (48-68) years, and serum T level was 421 (305-565) ng/dL; T levels did not change with patient age (p=0.78), but were inversely related with body mass index (BMI) (P<0.0001). An inverse relationship between plasma T level and the number of men with increased CV risk was observed for 6 of 7 cardiovascular markers, including IL-6, cTnI, TNF-α, ET, NTproBNP and leptin (Table 1). In men with T <250 ng/dL, after adjusting for age, BMI, hemoglobin A1c (HbA1c) levels, hsCRP and HDL cholesterol levels, IL-6, ET, NTproBNP, and leptin remained significantly associated with increased CV risk. As plama T levels increased, however, the fraction of men with marker values above the reference range, and therefore considered at increased risk, decreased (Figure 1). [B]Conclusions[/B] Our findings support prior reports demonstrating increased CV risk in hypogonadal men and argue against the controversial current clinical conclusion that men on testosterone therapy may have an increased incidence of CVD. [ATTACH=CONFIG]2073[/ATTACH] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Testosterone Replacement Decreases Biomarkers of Cardiovascular Disease
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top